A JournAl of the AmericAn DiAbetes AssociAtion

More documents

Recommendations

Info

Epidemiology/Geneticsstroke]), cancer, and a combined endpoint of the first of any of these. Timeto each endpoint was compared using Cox proportional hazards models. Asecondary endpoint was change in HbA1c between baseline and 1 year.26,278 patients initiated a common regimen. Sulfonylurea monotherapy hadsignificantly higher adjusted hazard ratios (aHR) for all-cause mortality, MACE,stroke and the combined endpoint. Metformin plus pioglitazone combinationtherapy had significantly lower adjusted aHRs for all-cause mortality and thecombined endpoint. Mean HbA1c improved between baseline and 12 monthsfor all regimens other than sulphonylurea monotherapy. Metformin plussulfonylurea was the most common second-line therapy but metformin pluspioglitazone was significantly superior for both all-cause mortality and thecombined endpoint. DPP-4s or rosiglitazone in combination with metforminalso had lower HRs for most endpoints but none achieved statisticalsignificance. Sulfonylurea monotherapy resulted in worst outcome. Figure.Summary of adjusted hazard ratios across the various endpoints by alternativeglucose-lowering regimen.Supported by: BMS, EASD, Cardiff University, Pharmatelligence67-LBPrediabetes Prevalence among U.S. Adults, NHANES 2005–2010:Comparisons of 2- and 6-Year Averaged EstimatesKAI M. BULLARD, SHARON H. SAYDAH, LINDA S. GEISS, DEBORAH B. ROLKA,DESMOND E. WILLIAMS, CATHERINE C. COWIE, CARL J. CASPERSEN, EDWARDGREGG, GIUSEPPINA IMPERATORE, Atlanta, GA, Bethesda, MDPrediabetes has been defined by at least 3 different measures: HbA1c5.7-6.4% (A1c); fasting plasma glucose 100-125 mg/dL (IFG); and 2-houroral glucose tolerance test 140-199 mg/dL (IGT). The National Health andNutrition Examination Survey (NHANES) is the nationally-representativesource for data on these measures in U.S. civilian, non-institutionalizedadults. Combining 2-year NHANES cycles is recommended to improveestimates’ precision and to minimize sampling error. However, examiningthe variation in 2-year estimates is needed before calculating averagedestimates. We used NHANES 2005-2010 data to compare 2-year prevalenceestimates for the 3 prediabetes measures and their combinations with6-year averages. Data were from the 7,806 participants aged ≥18 yearswho had all 3 prediabetes measures. The table shows prevalence estimates(95% confidence interval) by measure and survey period.Survey years (n)by prediabetesmeasureCycle 12005–2006(2213)ADA-Funded ResearchCycle 22007–2008(2686)Cycle 32009–2010(2907)All Years2005–2010(7806)A1c 14.0 (13.0-15.1) 18.9 (16.6-21.5) 23.2 (21.1-25.3) 18.8 (17.6-20.0)IFG 25.5 (22.5-28.7) 31.7 (28.7-35.0) 25.8 (23.0-28.8) 27.7 (25.9-29.5)IGT 13.4 (11.2-15.9) 15.1 (13.3-17.1) 11.6 (10.7-12.4) 13.3 (12.3-14.4)A1c or IFG 30.5 (27.9-33.3) 38.1 (35.3-41.0) 36.2 (33.1-39.4) 35.0 (33.3-36.7)A1c or IGT 21.3 (19.5-23.2) 26.3 (24.1-28.6) 26.5 (24.7-28.3) 24.7 (23.6-25.9)IFG or IGT 28.9 (26.0-32.0) 35.8 (32.5-39.3) 27.7 (25.5-29.9) 30.8 (29.1-32.5)A1c or IFG or IGT 32.8 (30.1-35.6) 40.5 (37.8-43.3) 36.5 (33.9-39.1) 36.6 (35.1-38.2)There was a significant increase in prediabetes prevalence between2005-2006 and 2007-2008 for all measures (p
Epidemiology/GeneticsThis preliminary evaluation of cheiro in the DCCT/EDIC cohort shows thatit is common in people with T1DM of long duration (~ 30 years), less frequentwith prior intensive therapy, and is related to glycemia and other factors.ResultsADA-Funded ResearchTotalCheiroarthropathyPresentCheiroarthropathyAbsentp-valueN 873 577 296Type of Cheiroarthropathy *269Frozen ShoulderCarpal Tunnel 264Trigger Finger 242Dupytren’s Contracture 78Positive Prayer Sign 171Age (years) 51.9±6.9 52.5±6.7 50.8±7.3 0.001Gender (female) 412 (47) 301 (52) 111 (38)
Page 2 and 3: Late Breaking AbstractsLate Breakin
Page 4 and 5: Acute and Chronic ComplicationsComp
Page 6 and 7: Behavioral Medicine, Clinical Nutri
Page 8 and 9: Behavioral Medicine, Clinical Nutri
Page 10 and 11: Clinical Diabetes/Therapeutics30-LB
Page 16 and 17: Clinical Diabetes/Therapeuticsperfo
Page 19: Epidemiology/GeneticsBlack with opt
Page 23: Immunology/TransplantationExpressio
Page 26: Insulin Signaling/Insulin Actionpar
Page 29 and 30: Integrated Physiology—MuscleInteg
Page 31 and 32: Integrated Physiology/Obesityresult
Page 33 and 34: Integrated Physiology/Obesity120-LB
Page 35 and 36: Islet Biology/Insulin Secretion128-
Page 37 and 38: Islet Biology/Insulin Secretion137-
Page 39 and 40: 145-LBParacrine Regulation of Human
Page 41 and 42: Neuropathy 8-LBNeurotransmitters 14
Page 43 and 44: Eckhoff, Devin, 80-LBEdeoga, Chimar
Page 45 and 46: Robinette, Leizleigh, 130-LBRoden,
Page 47 and 48: ABSTRACT Author DISCLOSURE INFORMAT
Page 49 and 50: AUTHOR RELATIONSHIP/COMPANY AUTHOR
Page 55: SAVE THE DATE!Join us in Chicago fo

A JournAl of the AmericAn DiAbetes AssociAtion

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?